Gilead Sciences, Inc. (GILD) Expected to Announce Quarterly Sales of $5.70 Billion
Wall Street analysts expect Gilead Sciences, Inc. (NASDAQ:GILD) to announce $5.70 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Gilead Sciences’ earnings. The lowest sales estimate is $5.27 billion and the highest is $6.05 billion. Gilead Sciences reported sales of $7.32 billion in the same quarter last year, which would suggest a negative year over year growth rate of 22.1%. The business is scheduled to issue its next earnings results on Tuesday, February 6th.
According to Zacks, analysts expect that Gilead Sciences will report full year sales of $5.70 billion for the current financial year, with estimates ranging from $25.42 billion to $26.21 billion. For the next year, analysts expect that the company will post sales of $22.15 billion per share, with estimates ranging from $19.77 billion to $23.47 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Gilead Sciences.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s quarterly revenue was down 13.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.75 earnings per share.
A number of research firms have recently commented on GILD. BidaskClub cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Mizuho reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 29th. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. Berenberg Bank reaffirmed a “buy” rating and set a $86.00 target price (up previously from $79.00) on shares of Gilead Sciences in a research note on Sunday, August 20th. Finally, Cowen Inc reaffirmed an “outperform” rating and set a $90.00 target price on shares of Gilead Sciences in a research note on Thursday, August 31st. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $84.87.
In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $83.11, for a total value of $6,094,705.63. Following the sale, the insider now owns 2,996,766 shares of the company’s stock, valued at approximately $249,061,222.26. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 666,819 shares of company stock valued at $52,303,086. 1.30% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of GILD. Welch Investments LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at $108,000. Harel Insurance Investments & Financial Services Ltd. increased its stake in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,400 shares during the period. Penserra Capital Management LLC increased its stake in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 144 shares during the period. Wealthcare Advisory Partners LLC acquired a new position in shares of Gilead Sciences during the third quarter worth about $133,000. Finally, American Beacon Advisors Inc. acquired a new position in shares of Gilead Sciences during the first quarter worth about $143,000. Institutional investors own 76.30% of the company’s stock.
Gilead Sciences (GILD) opened at $72.46 on Monday. The company has a market capitalization of $94,652.25, a P/E ratio of 7.56, a PEG ratio of -1.21 and a beta of 1.13. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $86.27. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.87%. Gilead Sciences’s payout ratio is 23.69%.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/gilead-sciences-inc-gild-expected-to-announce-quarterly-sales-of-5-70-billion/1728651.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.